Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 1
1993 7
1994 6
1995 7
1996 5
1997 10
1998 6
1999 5
2000 5
2001 12
2002 13
2003 19
2004 21
2005 23
2006 32
2007 17
2008 28
2009 21
2010 22
2011 19
2012 21
2013 38
2014 35
2015 32
2016 27
2017 32
2018 31
2019 22
2020 27
2021 20
2022 27
2023 28
2024 14

Text availability

Article attribute

Article type

Publication date

Search Results

560 results

Results by year

Filters applied: . Clear all
Page 1
Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions.
Handunnetti SM, Anderson MA, Burbury KI, Thompson PA, Burke G, Bressel M, Di Iulio JL, Hicks RJ, Westerman DA, Lade S, Pott C, Agarwal R, Koldej RM, Ritchie D, Dreyling M, Dawson MA, Dawson SJ, Seymour JF, Roberts AW, Tam CS. Handunnetti SM, et al. Among authors: seymour jf. Blood. 2024 Apr 25:blood.2023023388. doi: 10.1182/blood.2023023388. Online ahead of print. Blood. 2024. PMID: 38662991
Primary gastric diffuse large B-cell lymphoma: A multicentre retrospective study.
Lewis CS, Joy G, Jensen P, Barraclough A, Franco N, Talaulikar D, Hawkes EA, El-Galaly TC, Villa D, Dickinson M, Seymour JF, Cheah CY. Lewis CS, et al. Among authors: seymour jf. Br J Haematol. 2024 Apr 17. doi: 10.1111/bjh.19470. Online ahead of print. Br J Haematol. 2024. PMID: 38632873
Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.
Stilgenbauer S, Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek M, Hillmen P, Schneider C, Schetelig J, Böttcher S, Kater AP, Jiang Y, Boyer M, Popovic R, Ghanim MT, Moran M, Sinai WJ, Wang X, Mukherjee N, Chyla B, Wierda WG, Seymour JF. Stilgenbauer S, et al. Among authors: seymour jf. Blood Adv. 2024 Apr 23;8(8):1992-2004. doi: 10.1182/bloodadvances.2023011741. Blood Adv. 2024. PMID: 38290108 Free PMC article. Clinical Trial.
Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon.
Lew TE, Bennett R, Lin VS, Whitechurch A, Handunnetti SM, Marlton P, Shen Y, Mulligan SP, Casan J, Blombery P, Tam CS, Roberts AW, Seymour JF, Thompson PA, Anderson MA. Lew TE, et al. Among authors: seymour jf. Blood Adv. 2024 Mar 26;8(6):1439-1443. doi: 10.1182/bloodadvances.2023011327. Blood Adv. 2024. PMID: 38231032 Free PMC article. No abstract available.
560 results